Wearing-Off Effect Toward the End of Treatment Cycles in Patients With MS Receiving High-Efficacy Disease-Modifying Therapies: Data From Social Media Listening (P3-3.009)

Ivan John ClementJoanne FieldingMarie SerceauJanine RobinsonChinmay Deshpande2026-03-222026-03-22202310.1212/wnl.0000000000203254https://doi.org/10.1212/wnl.0000000000203254https://andeanlibrary.org/handle/123456789/73290To explore how various stakeholders (patients living with multiple sclerosis [PlwMS], caregivers [CGs], health care practitioners [HCPs], advocacy groups) describe symptoms, timing, coping strategies, and impact on quality of life (QoL) of the wearing-off effect (WOE) while receiving disease-modifying therapies (DMTs; natalizumab, ocrelizumab, ofatumumab, rituximab).enMedicineSocial mediaActive listeningPhysical therapyWearing-Off Effect Toward the End of Treatment Cycles in Patients With MS Receiving High-Efficacy Disease-Modifying Therapies: Data From Social Media Listening (P3-3.009)article